Abstract
Background and Aims Offering medications for opioid use disorder (MOUD) in carceral settings can significantly reduce overdose risk. However, it is unknown whether and to what extent individuals in U.S. jail settings continue MOUD once they leave incarceration, and what factors influence treatment continuity.
Design Retrospective cohort study of linked jail-based electronic health records and community OUD treatment claims.
Setting New York City Jail
Participants Incarcerations of individuals with OUD discharged from jail to the community between May 1, 2011 and December 31, 2017
Comparators Receiving vs. not receiving MOUD (methadone or buprenorphine) at the time of release from jail
Measurements We measured continuity of community-based MOUD treatment within one month of release, among those with and without MOUD during release from jail. We tested for effect modification based on MOUD receipt prior to incarceration and assessed factors associated with treatment discontinuation upon re-entry.
Findings Of 28,298 eligible incarcerations, 52.8% received MOUD at release. 30% of incarcerations with MOUD had a community-based MOUD claim within 30 days of release, compared to 7% of incarcerations without MOUD (Risk Ratio: 2.62 (2.44-2.82)). Most (69%) of those with MOUD claims prior to incarceration who received in-jail MOUD continued MOUD in the community, compared to only 9% of those without prior MOUD. Among incarcerations with MOUD at release, those who were younger, Non-Hispanic Black and with no history of MOUD treatment were less likely to continue treatment following release.
Conclusions MOUD maintenance in jail is strongly associated with MOUD continuity in the community upon release. Still, findings highlight a continued gap in MOUD upon-reentry, especially among those who initiate MOUD in jail. In the wake of worsening overdose deaths and troubling disparities, improving continuty of evidence-based care among this population must be an urgent policy priority.
Competing Interest Statement
NK receives compensation for expert testimony for ongoing opioid litigation
Funding Statement
Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R01DA045042-01A1. Dr. Krawczyk was further supported by NIDA K01DA055758. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Institutional Review Boards of the NYC Department of Health and Mental Hygiene (18-106), NYU Langone (i18-00445 and 1811019740), the Weill Cornell Medicine IRB under protocol #1811019740 and the Biomedical Research Alliance of New York (19-PRS-156-419(HHC)), and received certification from the Office for Human Research Protections of the US Department of Health and Human Services.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
# noa.krawczyk{at}nyulangone.org; keith.goldfeld{at}nyulangone.org, slim1{at}health.nyc.gov; tcherian1{at}health.nyc.gov; ewiewel{at}health.nyc.gov; braunstein{at}health.nyc.gov, zrosner{at}nychhc.org; mkatyal1{at}nychhc.org; rmacdonald{at}nychhc.org, AJ: alj4004{at}med.cornell.edu. SM: smm2010{at}med.cornell.edu, PJ: phj2003{at}med.cornell.edu
Data Availability
All data produced in the present study are protected and not publicly available or sharable due to sensitive nature of data (EHR, Medicaid claims, mortality records)